A team of researchers from Sweden, Scotland and Australia suggests that human genome may play a role in determining the makeup of the billions of microbes in the human gastrointestinal tract collectively known as the gut microbiota.

The team’s study, published in the journal Gut, identifies a link between human genes earlier associated with Crohn’s disease and the composition of human gastrointestinal bacteria.

“The hypothesis that our genes contribute to tailor-make our microbiota is very attractive. We still do not know whether certain DNA variations can result in the assembling and perpetuation of specific microbiota profiles, and this may bear important implications for the potential to treat common diseases through therapeutic modification of the gut flora,” said study senior author Prof Mauro D’Amato of the Karolinska Institutet, Sweden.

The microbiota, which evolved over tens of thousands of years alongside their human hosts, constitutes a complex and diverse community whose exact composition varies from person to person. It has numerous beneficial physiological and nutritional effects for humans; however, alterations in its bacterial composition have been linked to health problems including obesity and Crohn’s disease.

The team ran a statistical analysis on bacterial DNA sequenced from samples of intestinal tissue from 51 healthy people with no history of bowel conditions in relation to 30 specific genes. The genes have been shown to increase the risk of Crohn’s disease, and are likely to play an important role in gut-bacteria interactions. They found that DNA variation in one of these genes, known as IRGM, was associated with the presence of increased levels of a type of microbe known as Prevotella.

The study thus suggests that the IRGM gene could play a role in influencing the overall makeup of an individual’s microbiota, pushing it towards Prevotella dominance instead of an alternative community dominated by a closely related bacteria, Bacteroides.

Medical researchers are already considering therapeutic strategies to treat diseases by restoring ‘normal’ intestinal flora in patients by using pharmacological or dietary changes to create specific modifications in the gut microbiota.

Future research, expanding on the current study, could help to more effectively target these treatments.

“Primarily a proof-of-concept investigation, our pilot study reinforces the idea that large-scale analyses should be undertaken to unravel how variation in the entire human genome relates to variation in the human microbiota,” Prof D’Amato said.

“This is a small study but it could have important implications. We’ve provided further evidence that the human microbiome may also depend on the human genome, which invites serious investigation in the future,” added study lead author Dr Christopher Quince of the University of Glasgow’s School of Engineering.

_______

Bibliographic information: Christopher Quince et al. The impact of Crohn’s disease genes on healthy human gut microbiota: a pilot study. Gut, published online before print 7 January, 2013; doi: 10.1136/gutjnl-2012-304214